首页|无化疗放射治疗联合免疫检查点抑制剂治疗局部晚期非小细胞肺癌的研究进展

无化疗放射治疗联合免疫检查点抑制剂治疗局部晚期非小细胞肺癌的研究进展

扫码查看
对不可切除的局部晚期非小细胞肺癌(LA-NSCLC)患者,同步放化疗后维持免疫检查点抑制剂治疗仍是标准的治疗方案。部分LA-NSCLC患者因各种原因不适合化疗,表现在治疗方案选择中对无化疗方案的需求。近期研究表明,放射治疗联合免疫检查点抑制剂的治疗策略有良好协同效应和潜在治疗价值。本文主要对无化疗放射治疗联合免疫检查点抑制剂治疗不可切除的LA-NSCLC进行系统总结,有助于更好地了解该治疗模式的机制、优势和局限性,为临床实践提供更有针对性的指导。
Research progress of chemotherapy-free radiation therapy combined with immune checkpoint inhibitors in the treatment of locally advanced non-small cell lung cancer
For patients with unresectable locally advanced non-small cell lung cancer(LA-NSCLC),maintenance of immune checkpoint inhibitors after concomitant radiochemotherapy remains the standard treatment regimen.Some LA-NSCLC patients are not suitable for chemotherapy due to various reasons,manifested in the need for no chemotherapy regimen in the selection of treatment plans.Recent studies have shown that radiation therapy combined with immune checkpoint inhibitors have good synergistic effects and potential therapeutic value as a treatment strategy.This article mainly provides systematic summary of chemotherapy-free radiation therapy combined with immune checkpoint inhibitors in the treatment of unresectable LA-NSCLC,which helps to better understand mechanism,advantages,and limitations of this treatment mode,and provides more targeted guidance for clinical practice.

Chemotherapy-free regimenRadiotherapyImmune checkpoint inhibitorsLocally advanced non-small cell lung cancer

周婵、张小乔、张丽莎、陈彦辉、王梅芳

展开 >

湖北医药学院附属太和医院老年医学科,湖北十堰 442000

河北省唐山市曹妃甸区医院产科,河北唐山 063200

河北省唐山市曹妃甸区医院神经内分泌科,河北唐山 063200

湖北医药学院附属太和医院呼吸与危重症科,湖北十堰 442000

展开 >

无化疗方案 放射治疗 免疫检查点抑制剂 局部晚期非小细胞肺癌

湖北省卫生健康委员会2023-2024年度卫生健康科研立项项目

WJ2023M167

2024

中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
年,卷(期):2024.21(21)